Centerline Biomedical has raised $9.6M in financing since inception.
$3.8M in Seed funding in 2015-2016
$4.4M Series-A closed in December 2016
$1.26M CALF Loan in March 2017
$200K Competitive Grants
Our funding sources encompass:
- G2 Group Ventures
- Cleveland Clinic Foundation (CCF)
- Angel and private equity investors
- The Ohio Third Frontier Technology Validation and Start-up Fund (TVSF)
- The Great Lakes Innovation and Development Enterprise (GLIDE)
- The Ohio Third Frontier Commercialization Acceleration Loan Fund (CALF)
We plan for a $6M-$7M Series-B round in late 2017.
We continue to welcome conversations with those interested in helping us reach our goals. If you're interested in discussing an investment opportunity, please contact us today. For a better understanding of our innovative IOPS system and its many benefits for patients and caregivers, please download our whitepaper
Centerline believes that the addressable market for the initial application of IOPS technology is substantial due to the continued growth of minimally-invasive endovascular techniques, which are rapidly outpacing the current, more invasive aortic procedures. In addition, as graft technology advances, traditional endovascular procedures are beginning to trend towards increased complexity and procedure time. What does this mean for healthcare systems?
- Decreased operating room efficiency
- Increased cost from complicated, extended procedures
- Higher radiation exposure for caregivers and patients
In light of the rates of vascular disease confronting our aging population, simplifying these common procedures with tools like IOPS will become increasingly important.
Importantly, IOPS also represents a platform technology, meaning it is not limited to aortic procedures alone. This system can be adapted for use in other areas of vasculature where minimally-invasive procedures are preferable, such as those in the peripheral arteries, lungs and nervous system.